Achieve Life Sciences, Inc.
ACHV- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000949858
In the last 90 days, Achieve Life Sciences, Inc. insiders filed 0 open-market purchases and 1 sale; 111 institutions reported holding it in 13F filings for Q2 2026, worth $539.5M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Achieve Life Sciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $175.2K in total
- Insiders trading
- 1
- Net value
- −$175.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Achieve Life Sciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Stewart Richard Alistair | Director | 208,249 | Aug 21, 2026 | 3 |
| Sellig Thomas | Director | – | Jul 29, 2026 | 1 |
| Martin Christopher Nathan | Director | – | Jul 29, 2026 | 2 |
| Royston Aaron | Director | – | Jul 29, 2026 | 1 |
| Waldman Reid Alexander | Director | – | Jul 29, 2026 | 2 |
| Farrow Jeffrey S | Director | – | Jul 29, 2026 | 2 |
| Phelan Nancy R. | Director | – | Jul 29, 2026 | 1 |
| Goldberg Andrew D. | CEO and President | – | Apr 21, 2026 | 1 |
| Oki Mark K | Chief Financial Officer | 127,940 | Jan 30, 2026 | 1 |
| Wan Jerry | Principal Accounting Officer | 32,694 | Jan 30, 2026 | 1 |
| Xinos Jaime | Chief Commercial Officer | 74,432 | Jan 30, 2026 | 1 |
| Donnelly Craig | Chief Operations Officer | – | Jan 30, 2026 | 2 |
| Rubinstein Mark Lawrence | Chief Medical Officer | – | Jan 30, 2026 | 1 |
| Atkisson Erik | Chief Legal Officer | – | Dec 8, 2025 | 1 |
| Jacobs Cindy | President & CMO | 115,585 | Sep 8, 2025 | 0 |
| King Thomas Braxton | Director | 315,142 | Sep 8, 2025 | 0 |
| Martell Bridget A | Director | – | Jun 10, 2025 | 0 |
| Duty Stuart | Director | – | Jun 10, 2025 | 0 |
| Slaoui Kristen B. | Director | – | Jun 10, 2025 | 0 |
| Bencich John | CEO | 100,636 | Aug 20, 2024 | 0 |
| Himes Vaughn B | Director | – | Jan 24, 2024 | 0 |
| SVB Financial Group | 10% Owner | – | Nov 22, 2022 | 0 |
| SVB Innovation Credit Fund VIII, L.P. | 10% Owner | – | Nov 22, 2022 | 0 |
| Innovation Credit Fund VIII-A, L.P. | 10% Owner | – | Nov 22, 2022 | 0 |
| SVB Innovation Credit Partners VIII-A, LLC | 10% Owner | – | Nov 22, 2022 | 0 |
| SVB Innovation Credit Partners VIII, LLC | 10% Owner | – | Nov 22, 2022 | 0 |
| Moyes Jay M | Director | – | Jun 1, 2022 | 0 |
| Mattingly Martin A | Director | – | Jun 1, 2022 | 0 |
| Joseph Donald | Director | – | Jun 1, 2022 | 0 |
| Clarke Anthony | CSO | 3,502 | Apr 29, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Stewart Richard AlistairDirector | SSale | −20.6K | $8.49 | −$175.2K | −9.0%208.2K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Oki Mark KChief Financial Officer | SSale | −50.1K | $2.92 | −$146.2K | −28.1%127.9K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Stewart Richard AlistairChief Executive Officer | SSale | −129.5K | $2.92 | −$378.1K | −36.1%228.9K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Wan JerryPrincipal Accounting Officer | SSale | −14.1K | $2.77 | −$39.0K | −30.1%32.7K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | King Thomas BraxtonDirector | SSale | −139.9K | $2.77 | −$387.4K | −30.7%315.1K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Jacobs CindyPresident & CMO | SSale | −27.6K | $2.77 | −$76.5K | −19.3%115.6K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Xinos JaimeChief Commercial Officer | SSale | −20.9K | $2.77 | −$57.8K | −21.9%74.4K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Oki Mark KChief Financial Officer | PPurchase | +10.0K | $2.89 | +$28.9K | New position10.0K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Stewart Richard AlistairChieve Executive Officer | PPurchase | +10.0K | $2.86 | +$28.6K | +19.7%60.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Stewart Richard AlistairExecutive Chairman | PPurchase | +10.0K | $4.59 | +$45.9K | +35.1%38.5K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Stewart Richard AlistairExecutive Chairman | PPurchase | +10.0K | $0.00 | $0 | –10.0K after | Derivative |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Bencich JohnCEO | PPurchase | +10.0K | $4.59 | +$45.9K | +15.0%76.7K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Bencich JohnCEO | PPurchase | +10.0K | $0.00 | $0 | –10.0K after | Derivative |
| Jun 1, 2023 (view filing) | May 30 | 2 days | Bencich JohnCEO | PPurchase | +5.00K | $5.50 | +$27.5K | +8.1%66.7K after | |
| Nov 21, 2022 (view filing) | Nov 18 | 3 days | Bencich JohnCEO | PPurchase | +22.0K | – | – | +147.5%36.9K after | |
| Nov 21, 2022 (view filing) | Nov 18 | 3 days | Bencich JohnCEO | PPurchase | +11.0K | – | – | –11.0K after | Derivative |